Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Adagrasib in Chinese Patients with KRAS G12C Mutated Solid Tumors
NCT05263986Phase 1Unknown
- Sponsor
- Zai Lab
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib in solid tumor, sponsored by Zai Lab. Primary endpoints: Maximum Plasma Concentration at 2 weeks, Time to Maximum Plasma Concentration at 2 weeks and 1 more. Status: unknown.
02
Drugs
adagrasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05263986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263986.